Profile data is unavailable for this security.
About the company
Assertio Holdings, Inc. is a pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.
- Revenue in USD (TTM)137.35m
- Net income in USD-28.92m
- Incorporated2020
- Employees58.00
- LocationAssertio Holdings Inc100 S. Saunders Road, Suite 300LAKE FOREST 60045United StatesUSA
- Phone+1 (224) 419-7106
- Fax+1 (302) 636-5454
- Websitehttps://www.assertiotx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nasus Pharma Ltd | 0.00 | -1.19m | 56.09m | -- | -- | -- | -- | -- | -0.1319 | -0.1383 | 0.00 | -0.4762 | 0.00 | -- | -- | -- | -373.32 | -- | -- | -- | -- | -- | -- | -- | -- | -2.51 | -- | -- | -- | -- | -54.23 | -- | -- | -- |
| ImmuCell Corp | 27.77m | 2.32m | 59.43m | 70.00 | 25.39 | 1.99 | 11.84 | 2.14 | 0.2588 | 0.2588 | 3.09 | 3.29 | 0.6159 | 1.90 | 11.42 | 402,453.60 | 5.15 | -5.35 | 5.69 | -5.77 | 40.93 | 36.02 | 8.37 | -11.87 | 1.76 | 6.47 | 0.2415 | -- | 51.64 | 14.06 | 62.65 | -- | -19.66 | -- |
| LifeVantage Corp | 210.05m | 7.86m | 59.49m | 232.00 | 7.75 | 1.80 | 5.52 | 0.2832 | 0.5998 | 0.5998 | 16.16 | 2.58 | 3.24 | 2.45 | 96.73 | 905,370.70 | 12.12 | 9.17 | 18.91 | 14.08 | 78.75 | 80.73 | 3.74 | 2.93 | 1.03 | -- | 0.00 | 35.06 | 14.17 | -0.3794 | 233.84 | -3.22 | -12.55 | -- |
| Janel Corp | 212.13m | 5.02m | 61.37m | 353.00 | 12.42 | 2.60 | 6.94 | 0.2893 | 4.17 | 4.17 | 175.99 | 19.89 | 1.48 | 32.91 | 3.83 | 600,929.20 | 3.97 | 1.76 | 13.95 | 5.33 | 32.04 | 26.69 | 2.69 | 0.9608 | 0.7095 | 3.62 | 0.5020 | 0.00 | 13.24 | 20.27 | 2,155.61 | -- | -14.58 | -- |
| Rafael Holdings Inc | 1.03m | -31.33m | 65.74m | 21.00 | -- | 0.781 | -- | 63.89 | -0.8471 | -0.8471 | 0.0284 | 1.63 | 0.0107 | -- | 3.35 | 49,000.00 | -32.33 | -45.03 | -37.62 | -51.75 | 89.70 | -- | -3,034.89 | -8,772.74 | 3.98 | -- | 0.0074 | -- | 43.96 | -28.51 | 11.30 | -- | -47.65 | -- |
| Scilex Holding Co | 40.36m | -375.84m | 69.71m | 30.00 | -- | -- | -- | 1.73 | -33.18 | -33.18 | 4.08 | -28.88 | 0.2145 | 7.27 | 1.85 | 350,956.50 | -177.73 | -- | -- | -- | 68.59 | 75.06 | -828.56 | -176.54 | 0.0429 | -3.76 | -- | -- | 21.07 | 21.89 | 56.40 | -- | -49.14 | -- |
| Cumberland Pharmaceuticals, Inc. | 41.28m | -3.33m | 73.59m | 91.00 | -- | 2.82 | 58.31 | 1.78 | -0.2331 | -0.2331 | 2.79 | 1.75 | 0.5788 | 1.72 | 3.80 | 453,608.30 | -4.68 | -6.88 | -7.60 | -9.65 | 84.49 | 80.74 | -8.09 | -15.89 | 1.11 | -28.41 | 0.1688 | -- | -4.26 | 1.95 | -3.19 | -- | -29.32 | -- |
| Assertio Holdings Inc | 137.35m | -28.92m | 74.82m | 58.00 | -- | 0.7072 | 33.90 | 0.5447 | -4.71 | -4.71 | 20.93 | 16.49 | 0.4611 | 1.35 | 1.47 | 2,368,138.00 | -9.71 | -15.74 | -17.07 | -24.19 | 68.16 | 82.29 | -21.06 | -42.01 | 1.43 | -- | 0.2702 | -- | -17.83 | -11.45 | 93.50 | -- | -- | -- |
| Pliant Therapeutics Inc | 0.00 | -175.50m | 79.88m | 171.00 | -- | 0.3988 | -- | -- | -2.87 | -2.87 | 0.00 | 3.26 | 0.00 | -- | -- | 0.00 | -48.60 | -38.70 | -52.81 | -41.26 | -- | -- | -- | -1,044.87 | -- | -- | 0.1319 | -- | -100.00 | -- | -30.35 | -- | 31.90 | -- |
| Polypid Ltd | 0.00 | -34.17m | 81.10m | 69.00 | -- | 7.05 | -- | -- | -2.26 | -2.26 | 0.00 | 0.6028 | 0.00 | -- | -- | 0.00 | -143.79 | -105.84 | -252.10 | -143.44 | -- | -- | -- | -- | 1.82 | -27.54 | 0.0826 | -- | -- | -- | -17.73 | -- | -23.10 | -- |
| Pelthos Therapeutics Inc | 7.41m | -23.58m | 85.29m | 4.00 | -- | 1.40 | -- | 11.52 | -17.09 | -17.09 | 6.02 | 18.85 | 0.1152 | -- | -- | 1,851,500.00 | -36.68 | -- | -47.05 | -- | 68.73 | -- | -318.41 | -- | 1.04 | -12.32 | 0.00 | -- | -- | -- | -7.78 | -- | -- | -- |
| Verrica Pharmaceuticals Inc | 30.83m | -26.01m | 87.46m | 71.00 | -- | -- | -- | 2.84 | -3.44 | -3.44 | 3.50 | -1.80 | 0.8352 | 1.09 | 8.75 | 434,211.30 | -70.48 | -71.91 | -217.79 | -111.91 | 91.36 | -- | -84.38 | -729.00 | 1.18 | -1.70 | 1.94 | -- | 47.66 | -- | -14.31 | -- | -47.58 | -- |
| Biostem Technologies Inc | 235.17m | 20.20m | 94.62m | 67.00 | 6.25 | 1.89 | 4.63 | 0.4023 | 0.9019 | 0.9019 | 11.60 | 2.98 | 2.82 | 2.61 | 4.65 | -- | 24.25 | -- | 55.07 | -- | 97.33 | -- | 8.59 | -- | 4.09 | -- | 0.0566 | -- | 1,708.93 | -- | 475.86 | -- | -- | -- |
Data as of Mar 02 2026. Currency figures normalised to Assertio Holdings Inc's reporting currency: US Dollar USD
27.62%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nantahala Capital Management LLCas of 31 Dec 2025 | 587.34k | 9.15% |
| Opaleye Management, Inc.as of 31 Dec 2025 | 285.00k | 4.44% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 260.79k | 4.06% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 190.70k | 2.97% |
| Edgewood Management LLCas of 31 Dec 2025 | 107.52k | 1.68% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 90.03k | 1.40% |
| WBS H�nicke Verm�gensverwaltung GmbHas of 31 Dec 2025 | 87.40k | 1.36% |
| Geode Capital Management LLCas of 31 Dec 2025 | 69.07k | 1.08% |
| CM Management LLCas of 31 Dec 2025 | 50.00k | 0.78% |
| Citadel Securities LLCas of 31 Dec 2025 | 44.71k | 0.70% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
